Market cap
₹93 Cr
Revenue (TTM)
₹28 Cr
P/E Ratio
87.9
P/B Ratio
11.4
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 42.37 | 362.43 | 76.89 | 17.02 | 1.08 |
| EBIT | -630.09 | -0.27 | -24.39 | -486.52 | -207.10 |
| Net Profit | -92.18 | 108.28 | 127.53 | 54.40 | -11.50 |
| EPS | -95.75 | 104.50 | 120.68 | 52.63 | -12.86 |
| Book Value | -- | -- | -154.12 | -213.02 | -211.83 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| -29.05 | -16.25 | -13.66 | -38.41 | -2.76 |
| Net Margin
| -31.14 | -18.66 | 3.31 | -34.21 | -7.41 |
| Return on equity
| -92.48 | -55.27 | -- | 0.00 | 0.00 |
| Return on Capital
| -55.44 | -31.15 | -- | -76.70 | -29.88 |
| Return on Assets
| -21.96 | -13.15 | 3.80 | -18.60 | -12.36 |
| Debt to Equity (x)
| -- | -- | 1.18 | -1.96 | -4.07 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
--
|
-76.70
|
-29.88
|
-59.76
|
3.96
|
|
Peer Median
|
--
|
23.14
|
30.15
|
25.60
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
--
|
--
|
--
|
-277.44
|
-2.26
|
|
Peer Median
|
19.26
|
18.10
|
22.45
|
20.46
|
--
|
ROA
3.80
Lower than Peers by 9.33
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
3.80
|
-18.60
|
-12.36
|
-34.91
|
-0.58
|
|
Peer Median
|
13.13
|
12.99
|
14.45
|
12.89
|
--
|
EBIT Margin
-13.66
Lower than Peers by 31.27
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
-13.66
|
-38.41
|
-2.76
|
-45.97
|
2.46
|
|
Peer Median
|
17.61
|
18.02
|
14.69
|
13.67
|
--
|
Net Margin
3.31
Lower than Peers by 10.53
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
3.31
|
-34.21
|
-7.41
|
-51.80
|
-0.67
|
|
Peer Median
|
13.84
|
15.63
|
10.45
|
10.62
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
--
|
-25.97
|
-3.77
|
-36.54
|
11.50
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
76.89
Higher than Peers by 71.68
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
76.89
|
-57.06
|
155.17
|
-28.23
|
-15.57
|
|
Peer Median
|
5.20
|
16.83
|
6.12
|
2.92
|
--
|
EBIT Growth
-24.39
Lower than Peers by 36.79
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
-24.39
|
-498.76
|
84.71
|
-1,438.89
|
-39.45
|
|
Peer Median
|
12.40
|
19.84
|
-1.86
|
24.62
|
--
|
Net Profit Growth
127.53
Higher than Peers by 109.60
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
127.53
|
-98.62
|
63.59
|
-5,425.72
|
-173.54
|
|
Peer Median
|
17.93
|
24.00
|
1.68
|
29.22
|
--
|
EPS Growth
120.68
Higher than Peers by 108.21
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
120.68
|
-98.62
|
63.59
|
-5,424.95
|
-173.56
|
|
Peer Median
|
12.47
|
23.21
|
-4.71
|
32.56
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
--
|
-154.12
|
-346.40
|
-112.73
|
6.55
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
1.18
Higher than Peers by 1.18
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
1.18
|
-1.96
|
-4.07
|
56.07
|
0.98
|
|
Peer Median
|
0.00
|
0.11
|
0.05
|
0.06
|
--
|
Current Ratio
1.41
Lower than Peers by 0.78
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
1.41
|
0.74
|
0.69
|
0.63
|
1.06
|
|
Peer Median
|
2.19
|
2.09
|
2.06
|
1.89
|
--
|
Quick Ratio
1.13
Lower than Peers by 0.41
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
1.13
|
0.39
|
0.43
|
0.37
|
0.45
|
|
Peer Median
|
1.54
|
1.48
|
1.76
|
1.37
|
--
|
Interest Coverage
0.49
Lower than Peers by 24.45
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
0.49
|
-3.71
|
-3.09
|
-8.08
|
1.12
|
|
Peer Median
|
24.94
|
26.85
|
36.81
|
37.17
|
--
|
Operating Efficiency
Debtors to sales
41.75
Higher than Peers by 27.61
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
41.75
|
26.11
|
4.53
|
16.43
|
4.04
|
|
Peer Median
|
14.14
|
17.31
|
13.72
|
13.52
|
--
|
Asset Turnover
0.99
Lower than Peers by 0.06
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
0.99
|
0.54
|
1.66
|
0.67
|
0.87
|
|
Peer Median
|
1.05
|
1.07
|
1.12
|
1.27
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
--
|
66.89
|
20.01
|
40.27
|
15.38
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
--
|
168.22
|
36.94
|
110.64
|
84.70
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
--
|
453.49
|
149.20
|
311.96
|
338.42
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
--
|
-218.39
|
-92.25
|
-161.05
|
-238.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
87.92
Higher than Peers by 36.32
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
87.92
|
--
|
--
|
--
|
--
|
|
Peer Median
|
51.61
|
51.61
|
55.67
|
50.55
|
--
|
Price / Book Value
11.44
Higher than Peers by 3.15
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
11.44
|
-1.55
|
-5.86
|
-17.63
|
2.39
|
|
Peer Median
|
8.29
|
8.29
|
10.68
|
9.96
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.86
|
0.86
|
0.65
|
0.54
|
--
|
EV/EBITDA
46.49
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
46.49
|
-6.14
|
80.88
|
-4.97
|
7.10
|
|
Peer Median
|
--
|
44.75
|
38.80
|
44.18
|
--
|
Market Cap
93
Lower than Peers by 53,945
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Parmax Pharma
|
93
|
11
|
16
|
11
|
11
|
|
Peer Median
|
54,038
|
54,038
|
65,716
|
53,574
|
--
|